Olufunmilayo I Olopade

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7150594/publications.pdf

Version: 2024-02-01

242 papers	17,780 citations	20036 63 h-index	19470 122 g-index
254 all docs	254 docs citations	254 times ranked	25164 citing authors

#	Article	IF	Citations
1	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	3.0	19
2	Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center. Annals of Surgical Oncology, 2022, 29, 1423-1432.	0.7	9
3	ASO Visual Abstract: ProfileÂofÂPathogenicÂMutations andÂEvaluation ofÂGermlineÂGenetic TestingÂCriteria inÂConsecutiveÂBreast Cancer Patients Treated at a North Indian Tertiary Care Center. Annals of Surgical Oncology, 2022, 29, 1435-1436.	0.7	0
4	THE EFFECT OF ALPHA THALASSEMIA, HBF and HBC ON HAEMATOLOGICAL PARAMETERS OF SICKLE CELL DISEASE PATIENTS IN IBADAN, NIGERIA.. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022001.	0.5	1
5	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
6	Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer. Cancer Research, 2022, 82, OT1-10-02-OT1-10-02.	0.4	2
7	Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil. Breast Cancer Research and Treatment, 2022, 193, 485-494.	1.1	5
8	Differences in somatic TP53 mutation type in breast tumors by race and receptor status. Breast Cancer Research and Treatment, 2022, 192, 639-648.	1.1	7
9	Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. Scientific Reports, 2022, 12, 4190.	1.6	21
10	Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1351-1358.	1.1	3
11	Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach. Human Molecular Genetics, 2022, 31, 3133-3143.	1.4	11
12	Oncology Training Needs Assessment Among Health Care Professionals in Nigeria. JCO Global Oncology, 2022, , .	0.8	0
13	Innovative Strategies for Developing Biomarker-Informed Cancer Clinical Trials to Accelerate Progress in Precision Oncology in Sub-Saharan Africa. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 438-446.	1.8	0
14	Racial differences in interest and use of integrative medicine among patients with breast cancer.. Journal of Clinical Oncology, 2022, 40, 12101-12101.	0.8	0
15	Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer. PLoS ONE, 2022, 17, e0268693.	1.1	6
16	A breast cancer (BC) risk model incorporating Tyrer-Cuzick version 8 (TCv8) and a polygenic risk score (PRS) for diverse ancestries.. Journal of Clinical Oncology, 2022, 40, 557-557.	0.8	1
17	Adapting a medical school cancer research education program to the virtual environment.. Journal of Clinical Oncology, 2022, 40, 11029-11029.	0.8	0
18	Real-world evidence on predictors of survival for hormone-positive and triple-negative advanced breast cancer by treatment and BRCA status in the United States.. Journal of Clinical Oncology, 2022, 40, e18754-e18754.	0.8	0

#	Article	IF	Citations
19	Assessing response to neoadjuvant docetaxel and trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA).. Journal of Clinical Oncology, 2022, 40, TPS622-TPS622.	0.8	0
20	Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. Breast Cancer Research and Treatment, 2021, 185, 841-849.	1.1	25
21	The BRCA1 Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms. Cancer Research, 2021, 81, 1540-1551.	0.4	6
22	Breast cancer risk after age 60 amongÂBRCA1 andÂBRCA2 mutation carriers. Breast Cancer Research and Treatment, 2021, 187, 515-523.	1.1	5
23	Comparison of DCE-MRI of murine model cancers with a low dose and high dose of contrast agent. Physica Medica, 2021, 81, 31-39.	0.4	4
24	Reply to Q. Chu et al. JCO Global Oncology, 2021, 7, 185-186.	0.8	0
25	Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. Breast Cancer Research, 2021, 23, 18.	2.2	27
26	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5.8	19
27	Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer. Cancer, 2021, 127, 1827-1835.	2.0	19
28	Breast Cancer Research to Support Evidence-Based Medicine in Nigeria: A Review of the Literature. JCO Global Oncology, 2021, 7, 384-390.	0.8	0
29	Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry. Journal of the National Cancer Institute, 2021, 113, 1168-1176.	3.0	41
30	Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry. American Journal of Human Genetics, 2021, 108, 564-582.	2.6	18
31	Ancestrally unbiased polygenic breast cancer (BC) risk assessment.. Journal of Clinical Oncology, 2021, 39, 10502-10502.	0.8	3
32	Validation of the RSClin risk calculator using the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2021, 39, 549-549.	0.8	0
33	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
34	Precision oncology: Directing genomics and pharmacogenomics toward reducing cancer inequities. Cancer Cell, 2021, 39, 730-733.	7.7	13
35	Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women. Nature Communications, 2021, 12, 4198.	5.8	24
36	Addressing health disparities in cancer with genomics. Nature Reviews Genetics, 2021, 22, 621-622.	7.7	11

#	Article	IF	Citations
37	The impact of coronavirus disease 2019 on the quality of life and treatment disruption of patients with breast cancer in a multiethnic cohort. Cancer, 2021, 127, 4072-4080.	2.0	23
38	Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial. Applied Immunohistochemistry and Molecular Morphology, 2021, Publish Ahead of Print, 27-35.	0.6	1
39	Abstract 879: Validation of the Nigerian Breast Cancer Study model for predicting individual breast cancer risk in Cameroon and Uganda. , 2021, , .		0
40	The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nature Communications, 2021, 12, 4423.	5.8	111
41	Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2038-2043.	1.1	6
42	Feasibility of genetic testing for cancer risk assessment programme in Nigeria. Ecancermedicalscience, 2021, 15, 1283.	0.6	2
43	Doing better and being better in breast cancer care: an interview with Funmi Olopade. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	3
44	Epidemiology of Triple-Negative Breast Cancer. Cancer Journal (Sudbury, Mass), 2021, 27, 8-16.	1.0	126
45	The global role, impact, and limitations of Community Health Workers (CHWs) in breast cancer screening: a scoping review and recommendations to promote health equity for all. Global Health Action, 2021, 14, 1883336.	0.7	20
46	Associations between age of menarche and genetic variation in women of African descent: genome-wide association study and polygenic score analysis. Journal of Epidemiology and Community Health, 2021, , jech-2020-216000.	2.0	1
47	Assessment of Breast Cancer Management in Sub-Saharan Africa. JCO Global Oncology, 2021, 7, 1593-1601.	0.8	5
48	Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nature Communications, 2021, 12, 6946.	5.8	22
49	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
50	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
51	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	0.8	270
52	Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Research, 2020, 80, 394-405.	0.4	48
53	Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 359-367.	1.1	36
54	p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability. Nature Communications, 2020, 11, 5007.	5.8	8

#	Article	IF	Citations
55	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2020, 159, 820-826.	0.6	10
56	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
57	Implementing oncology clinical trials in Nigeria: a model for capacity building. BMC Health Services Research, 2020, 20, 713.	0.9	11
58	Global disparities in breast cancer outcomes: new perspectives, widening inequities, unanswered questions. The Lancet Global Health, 2020, 8, e978-e979.	2.9	13
59	Association of Event-Free and Distant Recurrenceâ€“Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. JAMA Oncology, 2020, 6, 1355.	3.4	119
60	Magnetic resonance angiography reveals increased arterial blood supply and tumorigenesis following high fat feeding in a mouse model of tripleâ€negative breast cancer. NMR in Biomedicine, 2020, 33, e4363.	1.6	4
61	Black Lives Matter Worldwide: Retooling Precision Oncology for True Equity of Cancer Care. Cell Reports Medicine, 2020, 1, 100079.	3.3	6
62	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
63	Longitudinal follow-up after telephone disclosure in the randomized COGENT study. Genetics in Medicine, 2020, 22, 1401-1406.	1.1	4
64	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	1.6	2
65	Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base. Cancer, 2020, 126, 4013-4022.	2.0	23
66	Breast Cancer Knowledge Assessment of Health Workers in Ibadan, Southwest Nigeria. JCO Global Oncology, 2020, 6, 387-394.	0.8	5
67	Traditional medicine usage among adult women in Ibadan, Nigeria: a cross-sectional study. BMC Complementary Medicine and Therapies, 2020, 20, 93.	1.2	17
68	Infrastructural Challenges Lead to Delay of Curative Radiotherapy in Nigeria. JCO Global Oncology, 2020, 6, 269-276.	0.8	20
69	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	3.4	48
70	Implementing newborn screening for sickle cell disease as part of immunisation programmes in Nigeria: a feasibility study. Lancet Haematology,the, 2020, 7, e534-e540.	2.2	35
71	Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet?. Breast Cancer Research and Treatment, 2020, 183, 243-250.	1.1	6
72	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32

#	Article	IF	Citations
73	Formal Assessment of Teamwork Among Cancer Health Care Professionals in Three Large Tertiary Centers in Nigeria. JCO Global Oncology, 2020, 6, 560-568.	0.8	5
74	Results from MAGENTA: A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic counseling during online testing for breast and ovarian cancer genetic risk.. Journal of Clinical Oncology, 2020, 38, 1506-1506.	0.8	13
75	Abstract 2320: Evaluating a polygenic risk score for breast cancer in women of African ancestry. , 2020, , .		1
76	Abstract 4613: Cross-ancestry genome-wide association study identifies six new loci for breast cancer in women of African and european ancestry. , 2020, , .		1
77	LXR/RXR pathway signaling associated with triple-negative breast cancer in African American women. Breast Cancer: Targets and Therapy, 2019, Volume 11, 1-12.	1.0	10
78	USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan. JAMA Network Open, 2019, 2, e1910142.	2.8	9
79	Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Medicine, 2019, 8, 5609-5618.	1.3	10
80	Radiogenomics of breast cancer using dynamic contrast enhanced MRI and gene expression profiling. Cancer Imaging, 2019, 19, 48.	1.2	48
81	The Time for Mainstreaming Germline Testing for Patients With Breast Cancer Is Now. Journal of Clinical Oncology, 2019, 37, 2177-2178.	0.8	10
82	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	2.3	28
83	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	1.6	5
84	Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Cell Death and Disease, 2019, 10, 666.	2.7	19
85	Breast Cancer Riskâ€“Associated SNPs in the mTOR Promoter Form De Novo KLF5- and ZEB1-Binding Sites that Influence the Cellular Response to Paclitaxel. Molecular Cancer Research, 2019, 17, 2244-2256.	1.5	8
86	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
87	Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. British Journal of Cancer, 2019, 120, 398-403.	2.9	25
88	The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries. Human Mutation, 2019, 40, e1-e23.	1.1	34
89	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19
90	Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. International Journal of Cancer, 2019, 145, 3321-3333.	2.3	16

#	Article	IF	Citations
91	BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796.	1.1	26
92	Metabolically activated adipose tissue macrophages link obesity to triple-negative breast cancer. Journal of Experimental Medicine, 2019, 216, 1345-1358.	4.2	80
93	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
94	Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis. Molecular Cancer Therapeutics, 2019, 18, 873-885.	1.9	69
95	Association study in African-admixed populations across the Americas recapitulates asthma risk loci in non-African populations. Nature Communications, 2019, 10, 880.	5.8	71
96	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2019, 175, 443-449.	1.1	12
97	N-acetyltransferase 2 enzyme genotypeâ€“phenotype discordances in both HIV-negative and HIV-positive Nigerians. Pharmacogenetics and Genomics, 2019, 29, 106-113.	0.7	7
98	Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers. Clinical Cancer Research, 2019, 25, 1786-1794.	3.2	44
99	Assembly of a pan-genome from deep sequencing of 910 humans of African descent. Nature Genetics, 2019, 51, 30-35.	9.4	276
100	Preferences for inâ€person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. Clinical Genetics, 2019, 95, 293-301.	1.0	16
101	Identification of novel common breast cancer risk variants at the 6q25 locusÂamong Latinas. Breast Cancer Research, 2019, 21, 3.	2.2	32
102	Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?. Cancer, 2019, 125, 213-222.	2.0	28
103	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	3.0	30
104	Implementation of a Novel Medical School Multidisciplinary and Interprofessional Oncology Curriculum: a Mixed Method Study. Journal of Cancer Education, 2019, 34, 50-55.	0.6	10
105	Race, the microbiome and colorectal cancer. World Journal of Gastrointestinal Oncology, 2019, 11, 773-787.	0.8	18
106	Genomic profiling of residual tumor after neoadjuvant chemotherapy for breast cancer.. Journal of Clinical Oncology, 2019, 37, e12106-e12106.	0.8	0
107	Determining clinical relevance of genomic heterogeneity in an ethnically diverse cohort of newly diagnosed patients with breast cancer.. Journal of Clinical Oncology, 2019, 37, 3084-3084.	0.8	0
108	Survey of medical student knowledge in oncology and survivorship care in Nigeria: A pilot study.. Journal of Clinical Oncology, 2019, 37, e18106-e18106.	0.8	0

#	Article	IF	Citations
109	Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. Journal of the National Cancer Institute, 2018, 110, 985-993.	3.0	35
110	Development of a Breast Cancer Risk Prediction Model for Women in Nigeria. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 636-643.	1.1	16
111	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
112	Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Familial Cancer, 2018, 17, 495-505.	0.9	17
113	Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2018, 169, 561-571.	1.1	25
114	Breast Cancer Genetics Knowledge and Testing Intentions among Nigerian Professional Women. Journal of Genetic Counseling, 2018, 27, 863-873.	0.9	5
115	Household air pollution and chronic hypoxia in the placenta of pregnant Nigerian women: A randomized controlled ethanol Cookstove intervention. Science of the Total Environment, 2018, 619-620, 212-220.	3.9	25
116	Association of Pancreatic Cancer Susceptibility Variants with Risk of Breast Cancer in Women of European and African Ancestry. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 116-118.	1.1	5
117	Population-dependent Intron Retention and DNA Methylation in Breast Cancer. Molecular Cancer Research, 2018, 16, 461-469.	1.5	23
118	Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry. Breast Cancer Research and Treatment, 2018, 168, 703-712.	1.1	42
119	Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screeningâ€"Reply. JAMA Oncology, 2018, 4, 883.	3.4	0
120	Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. International Journal of Epidemiology, 2018, 47, 987-997.	0.9	11
121	Mutations in context: implications of BRCA testing in diverse populations. Familial Cancer, 2018, 17, 471-483.	0.9	23
122	Genetic variation in the vitamin D related pathway and breast cancer risk in women of African ancestry in the root consortium. International Journal of Cancer, 2018, 142, 36-43.	2.3	11
123	Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. Journal of the National Cancer Institute, 2018, 110, 176-182.	3.0	104
124	Knowledge of Genetic Counseling Among Patients With Breast Cancer and Their Relatives at a Nigerian Teaching Hospital. Journal of Global Oncology, 2018, 4, 1-8.	0.5	7
125	Inherited Breast Cancer in Nigerian Women. Journal of Clinical Oncology, 2018, 36, 2820-2825.	0.8	80
126	Use and Patient-Reported Outcomes of Clinical Multigene Panel Testing for Cancer Susceptibility in the Multicenter Communication of Genetic Test Results by Telephone Study. JCO Precision Oncology, 2018, 2, 1-12.	1.5	10

#	Article	IF	Citations
127	Genetic Ancestry May Influence the Evolutionary Trajectory of Cancers. Cancer Cell, 2018, 34, 529-530.	7.7	4
128	Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nature Communications, 2018, 9, 4181.	5.8	77
129	HIF-2Î± promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. Journal of Experimental and Clinical Cancer Research, 2018, 37, 256.	3.5	124
130	LncRNA BLAT1 is Upregulated in Basal-like Breast Cancer through Epigenetic Modifications. Scientific Reports, 2018, 8, 15572.	1.6	26
131	CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1364-1370.	1.1	23
132	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54
133	Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. Frontiers in Oncology, 2018, 8, 156.	1.3	26
134	Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry. Molecular Carcinogenesis, 2018, 57, 1311-1318.	1.3	6
135	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	9.4	184
136	Pre- and post-treatment body weight and prognosis in a multiethnic cohort of breast cancer patients.. Journal of Clinical Oncology, 2018, 36, 1501-1501.	0.8	1
137	An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. Journal of Racial and Ethnic Health Disparities, 2017, 4, 140-148.	1.8	10
138	Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States. JAMA Oncology, 2017, 3, 928.	3.4	28
139	Fast bilateral breast coverage with high spectral and spatial resolution (HiSS) MRI at 3T. Journal of Magnetic Resonance Imaging, 2017, 46, 1341-1348.	1.9	8
140	Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. JAMA Oncology, 2017, 3, 1654.	3.4	208
141	Household air pollution and angiogenic factors in pregnant Nigerian women: A randomized controlled ethanol cookstove intervention. Science of the Total Environment, 2017, 599-600, 2175-2181.	3.9	14
142	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
143	Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1016-1026.	1.1	24
144	Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prevention Research, 2017, 10, 255-266.	0.7	18

#	Article	IF	Citations
145	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
146	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
147	DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. Npj Breast Cancer, 2017, 3, 31.	2.3	64
148	A functionally significant SNP in TP53 and breast cancer risk in African-American women. Npj Breast Cancer, 2017, 3, 5.	2.3	44
149	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
150	Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer. PLoS Genetics, 2017, 13, e1006727.	1.5	14
151	Pilot Survey of Breast Cancer Management in Sub-Saharan Africa. Journal of Global Oncology, 2017, 3, 194-200.	0.5	23
152	Extended follow-up in the COGENT study: A randomized study of in-person versus telephone disclosure of cancer genetic test results.. Journal of Clinical Oncology, 2017, 35, 1504-1504.	0.8	0
153	Association of breast cancer risk in women of African ancestry with genetic variants in the TET-related DNA demethylation pathway.. Journal of Clinical Oncology, 2017, 35, e13015-e13015.	0.8	0
154	PREVALENCE AND AETIOLOGY OF BACTEREMIA IN FEBRILE CHILDREN WITH SICKLE CELL DISEASE AT A NIGERIAN TERTIARY HOSPITAL. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017039.	0.5	13
155	Identification of a circulating MicroRNA signature to distinguish recurrence in breast cancer patients. Oncotarget, 2016, 7, 55231-55248.	0.8	70
156	Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. Human Genetics, 2016, 135, 1145-1159.	1.8	32
157	Building local capacity for genomics research in Africa: recommendations from analysis of publications in Sub-Saharan Africa from 2004 to 2013. Global Health Action, 2016, 9, 31026.	0.7	45
158	Naturally occurringBRCA2alternative mRNA splicing events in clinically relevant samples. Journal of Medical Genetics, 2016, 53, 548-558.	1.5	69
159	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
160	Long-Term Disease-Free Survival in a Young Patient With Hormone Receptorâ€“Positive Breast Cancer and Oligometastatic Disease in the Brain. Clinical Breast Cancer, 2016, 16, e61-e63.	1.1	3
161	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
162	Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. Human Molecular Genetics, 2016, 25, ddw305.	1.4	50

#	Article	IF	Citations
163	Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. Breast Cancer Research and Treatment, 2016, 160, 121-129.	1.1	11
164	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	2.2	42
165	A continuum of admixture in the Western Hemisphere revealed by the African Diaspora genome. Nature Communications, 2016, 7, 12522.	5.8	136
166	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
167	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
168	Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapyâ€related leukemia. Cancer, 2016, 122, 304-311.	2.0	129
169	Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect. Cancer, 2016, 122, 1913-1920.	2.0	11
170	Î²-catenin regulatesc-MycandCDKN1Aexpression in breast cancer cells. Molecular Carcinogenesis, 2016, 55, 431-439.	1.3	48
171	Closing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2016, 94, 440-449.	0.4	23
172	The Breastâ€“Thyroid Cancer Link: A Systematic Review and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 231-238.	1.1	103
173	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
174	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	3.0	77
175	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
176	Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. PLoS ONE, 2016, 11, e0147145.	1.1	41
177	Genetic and Epigenetic Regulation of TOX3 Expression in Breast Cancer. PLoS ONE, 2016, 11, e0165559.	1.1	23
178	Breast cancer risk after fullâ€term pregnancies among A frican women from N igeria, C ameroon, and U ganda. Cancer, 2015, 121, 2237-2243.	2.0	11
179	A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. Ca-A Cancer Journal for Clinicians, 2015, 65, 221-238.	157.7	252
180	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26

#	Article	IF	Citations
181	Î²-Catenin Is Required for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells. PLoS ONE, 2015, 10, e0117097.	1.1	146
182	Race, Ethnicity, and the Diagnosis of Breast Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 141.	3.8	19
183	Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers. Breast, 2015, 24, 131-136.	0.9	21
184	Inherited predisposition to breast cancer among African American women. Breast Cancer Research and Treatment, 2015, 149, 31-39.	1.1	116
185	Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Targeted Oncology, 2015, 10, 501-508.	1.7	22
186	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
187	Mutation Spectrum and Risk of Colorectal Cancer in African American Families with Lynch Syndrome. Gastroenterology, 2015, 149, 1446-1453.	0.6	46
188	Triple Negative Breast Cancer in BRCA1 Mutation Carriers With a Complete RadiologicÂResponse to Neoadjuvant Paclitaxel: AÂCase Report. Clinical Breast Cancer, 2015, 15, e155-e158.	1.1	5
189	Effect of Oophorectomy on Survival After Breast Cancer inBRCA1andBRCA2Mutation Carriers. JAMA Oncology, 2015, 1, 306.	3.4	107
190	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
191	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell, 2015, 163, 506-519.	13.5	1,485
192	Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genetics in Medicine, 2015, 17, 485-492.	1.1	79
193	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
194	Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter. PLoS ONE, 2015, 10, e0142224.	1.1	20
195	Relationships between Plasma Micronutrients, Serum IgE, and Skin Test Reactivity and Asthma among School Children in Rural Southwest Nigeria. Journal of Biomarkers, 2014, 2014, 1-9.	1.0	11
196	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
197	Pilot study demonstrating potential association between breast cancer imageâ€based risk phenotypes and genomic biomarkers. Medical Physics, 2014, 41, 031917.	1.6	21
198	Differentiation and Loss of Malignant Character of Spontaneous Pulmonary Metastases in Patient-Derived Breast Cancer Models. Cancer Research, 2014, 74, 7406-7417.	0.4	37

#	Article	IF	Citations
199	Relationships between computer-extracted mammographic texture pattern features and BRCA1/2mutation status: a cross-sectional study. Breast Cancer Research, 2014, 16, 424.	2.2	44
200	A Preliminary Study of the Suitability of Archival Bone Marrow and Peripheral Blood Smears for Diagnosis of CML Using FISH. Advances in Hematology, 2014, 2014, 1-5.	0.6	6
201	A comprehensive examination of breast cancer risk loci in African American women. Human Molecular Genetics, 2014, 23, 5518-5526.	1.4	42
202	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
203	Building capacity for sustainable research programmes for cancer in Africa. Nature Reviews Clinical Oncology, 2014, 11, 251-259.	12.5	68
204	Relationships between computer-extracted mammographic texture pattern features and. Breast Cancer Research, 2014, 16, 424.	2.2	21
205	Alcohol Consumption and Breast Cancer Risk among Women in Three Sub-Saharan African Countries. PLoS ONE, 2014, 9, e106908.	1.1	43
206	Effect of stove intervention on household air pollution and the respiratory health of women and children in rural Nigeria. Air Quality, Atmosphere and Health, 2013, 6, 553-561.	1.5	42
207	A genome-wide association study of breast cancer in women of African ancestry. Human Genetics, 2013, 132, 39-48.	1.8	70
208	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244
209	Breast cancer surveillance in high-risk women with magnetic resonance imaging every 6 months.. Journal of Clinical Oncology, 2013, 31, 1506-1506.	0.8	6
210	Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis, 2012, 33, 835-840.	1.3	64
211	High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. International Journal of Cancer, 2012, 131, 1114-1123.	2.3	81
212	Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Research and Treatment, 2012, 134, 889-894.	1.1	42
213	Neoadjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): Efficacy and safety in a phase II feasibility study.. Journal of Clinical Oncology, 2012, 30, e11554-e11554.	0.8	0
214	Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Research and Treatment, 2011, 128, 703-711.	1.1	223
215	Association of Risk-Reducing Surgery in <emph type="ital">BRCA1</emph> or <emph type="ital">BRCA2</emph> Mutation Carriers With Cancer Risk and Mortality. JAMA - Journal of the American Medical Association, 2010, 304, 967.	3.8	1,241
216	Wnt/Î²-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome. American Journal of Pathology, 2010, 176, 2911-2920.	1.9	450

#	Article	IF	Citations
217	Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2009, 27, 4515-4521.	0.8	341
218	Prediction ofBRCAMutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. Journal of Clinical Oncology, 2009, 27, 1184-1190.	0.8	43
219	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948.	2.6	257
220	Advances in Breast Cancer: Pathways to Personalized Medicine. Clinical Cancer Research, 2008, 14, 7988-7999.	3.2	165
221	Targeting Health Disparities: A Model Linking Upstream Determinants To Downstream Interventions. Health Affairs, 2008, 27, 339-349.	2.5	220
222	RAD51 135Gâ†'C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	2.6	217
223	Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. International Journal of Cancer, 2007, 121, 2661-2667.	2.3	75
224	Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nature Reviews Cancer, 2007, 7, 937-948.	12.8	400
225	Disparities in Genetic Testing: Thinking Outside the BRCA Box. Journal of Clinical Oncology, 2006, 24, 2197-2203.	0.8	152
226	Disparities in Cancer Care: A Worldwide Perspective and Roadmap for Change. Journal of Clinical Oncology, 2006, 24, 2135-2136.	0.8	18
227	Genetic Testing in an Ethnically Diverse Cohort of High-Risk Women. JAMA - Journal of the American Medical Association, 2005, 294, 1925.	3.8	219
228	Confronting Genetic Testing Disparities. JAMA - Journal of the American Medical Association, 2005, 293, 1783.	3.8	76
229	Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group. Journal of Clinical Oncology, 2004, 22, 1055-1062.	0.8	1,095
230	Efficacy of Risk-Reducing Salpingo-Oophorectomy in Women with BRCA-1 and BRCA-2 Mutations. Breast Journal, 2004, 10, S5-S9.	0.4	63
231	FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell, 2003, 3, 417-420.	7.7	72
232	Breast cancer genetics in African Americans. Cancer, 2003, 97, 236-245.	2.0	153
233	Obesity and Height in Urban Nigerian Women with Breast Cancer. Annals of Epidemiology, 2003, 13, 455-461.	0.9	49
234	Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Research, 2002, 62, 1481-8.	0.4	70

#	Article	IF	Citations
235	Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q. , 2000, 28, 164-172.		18
236	Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Human Genetics, 2000, 107, 186-191.	1.8	103
237	Computerized analysis of mammographic parenchymal patterns for breast cancer risk assessment: Feature selection. Medical Physics, 2000, 27, 4-12.	1.6	78
238	Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: ?2-glycoprotein I antibodies as a marker of response to therapy. , 1999, 14, 171-176.		45
239	Codeletion ofCDKN2 andMTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. Genes Chromosomes and Cancer, 1998, 22, 72-78.	1.5	49
240	Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. , 1998, 22, 72.		2
241	CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia. British Journal of Haematology, 1995, 91, 865-870.	1.2	20
242	Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes and Cancer, 1990, 2, 147-158.	1.5	103